Research map: Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

Back to the article

Papers in this map

  1. New Equations to Estimate GFR in Children with CKD · George J. Schwartz · 2009 · 3830 citations · Cited by this paper
  2. Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial · Anne E M Kamphuis · 2026 · Cites this paper
  3. Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation · 2026 · Related
  4. Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children · Trevor N. Johnson · 2006 · 530 citations · Cited by this paper
  5. Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer · 2026 · Related
  6. In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor · Masanori Kobayashi · 2010 · 381 citations · Cited by this paper
  7. Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation · 2026 · Related
  8. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial · Jan van Lunzen · 2011 · 300 citations · Cited by this paper
  9. Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations · 2026 · Related
  10. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults · Sherene Min · 2011 · 221 citations · Cited by this paper
  11. A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics · 2026 · Related
  12. Establishing age/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods · Hans Pottel · 2008 · 200 citations · Cited by this paper
  13. Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva · 2026 · Related
  14. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children · Anna Turkova · 2021 · 132 citations · Cited by this paper
  15. Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing · 2026 · Related
  16. A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data · Farzaneh Salem · 2014 · 127 citations · Cited by this paper
  17. Impacts of Uremic Toxins on the Population Pharmacokinetics of Total Mycophenolic Acid and its Glucuronide Metabolite in Adult Kidney Transplant Recipients · 2026 · Related
  18. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial · Diana M. Gibb · 2013 · 118 citations · Cited by this paper
  19. Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty · 2026 · Related
  20. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter? · Brian R. Wood · 2021 · 68 citations · Cited by this paper
  21. ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma · 2026 · Related
  22. Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals · Rebecca Begley · 2018 · 53 citations · Cited by this paper
  23. Advancing the prevention and treatment of HIV in children: priorities for research and development · Martina Penazzato · 2022 · 37 citations · Cited by this paper
  24. Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients · Hyun-moon Back · 2019 · 35 citations · Cited by this paper
  25. Constructing a representative in‐silico population for paediatric simulations: Application to HIV‐positive African children · Roeland E. Wasmann · 2020 · 27 citations · Cited by this paper
  26. A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression · Xavier Sáez‐Llorens · 2014 · 21 citations · Cited by this paper
  27. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents · Hardik Chandasana · 2023 · 12 citations · Cited by this paper
  28. Evaluation of weight‐based prescription of antiretroviral therapy in children · Suba Dakshina · 2019 · 11 citations · Cited by this paper
  29. Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy · Eva Natukunda · 2025 · 3 citations · Cited by this paper
  30. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers · Lisanne A. H. Bevers · 2024 · 1 citation · Cited by this paper
  31. The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in HIV-associated Tuberculosis · Rephaim Mpofu · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)